AMPHASTAR PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Gayle Deflin

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gayle Deflin”): 37,568,636 for, 2,204,679 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 16,015,958 for, 1,348,166 against, 4,323 abstained.

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Howard Lee

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Howard Lee”): 30,735,084 for, 9,041,573 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 12,077,606 for, 5,286,518 against, 4,323 abstained.

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Mary Ziping Luo

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mary Ziping Luo”): 36,539,361 for, 3,238,762 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 15,779,001 for, 1,585,123 against, 4,323 abstained.

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Michael A. Zasloff

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael A. Zasloff”): 28,934,721 for, 10,836,431 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 11,105,723 for, 6,258,401 against, 4,323 abstained.

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

Description as filed by funds: To approve the amendment and restatement of our 2015 Equity Incentive Plan.

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“4. To approve, the amendment and restatement of the Company's 2015 Equity Incentive Plan (as amended and restated, the "2015 Equity Incentive Plan")”): 28,069,401 for, 11,693,213 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4: To approve, the amendment and restatement of the Company's 2015 Equity Incentive Plan (as amended and restated, the "2015 Equity Incentive Plan");”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of AMPHASTAR PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (3 managers, 1,229,081 against).

The 91 asset managers below reported 11,189,376 for, 4,943,221 against, 6,769 abstained.

Showing the 25 largest of 91 asset managers. See all 91 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers; and

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers; and”): 37,859,745 for, 1,833,819 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on a non-binding basis, the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 91 managers: 16,672,917 for, 691,050 against, 4,323 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 231 managers: 16,633,019 for, 1,575,091 against, 671 abstained, 58 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024;

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024”): 44,072,994 for, 586,017 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 17,363,608 for, 516 against, 4,323 abstained.

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.